Ofev is the brand name for the medication nintedanib, a targeted therapy classified under respiratory health. It is supplied as a 100 mg capsule and requires a prescription in Hong Kong. Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). The Hong Kong Department of Health aligns its approvals with major regulators such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Nintedanib belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). It blocks several intracellular enzymes-particularly the platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) receptors. By inhibiting these pathways, nintedanib reduces the proliferation of fibroblasts and the formation of excess scar tissue (fibrosis) within the lungs.
By slowing fibrotic progression, nintedanib helps preserve forced vital capacity (FVC), a key measure of lung function.
Both indications are approved by the FDA, EMA, and are recognized by Hong Kong’s health authority for use in adults with a confirmed diagnosis. Ofev is not indicated for asthma, chronic obstructive pulmonary disease (COPD), or acute respiratory infections.
Current peer-reviewed literature has explored nintedanib in other fibrotic disorders, such as:
These uses are not approved by regulatory agencies. Off-label use should only occur under close medical supervision with a thorough risk-benefit assessment.
If you take any other medication, supplement, or herbal product, inform your healthcare provider before starting Ofev.
Patients should contact their healthcare provider promptly if they experience persistent diarrhea, signs of liver injury (yellowing of skin/eyes), or unexplained shortness of breath.
This article provides educational information about Ofev (nintedanib) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Ofev can be co-prescribed with many inhaled therapies (e.g., bronchodilators) used for symptom control, but potential interactions with systemic agents such as anticoagulants or CYP3A4 modulators should be reviewed by a pharmacist or physician.
Contact your healthcare provider promptly. They may recommend dose reduction, temporary interruption, or supportive treatment such as loperamide, depending on severity.
Clinical practice often begins with 100 mg twice daily to assess tolerability, then increases to the approved 150 mg twice daily if the patient tolerates the lower dose. Your prescriber will decide the best approach.
Standard drug tests do not detect nintedanib. However, its impact on liver enzymes may be reflected in routine blood panels, which should be interpreted by a clinician.
Improvements in the rate of FVC decline are typically observed after several weeks of consistent therapy, but the drug does not reverse existing fibrosis; it slows further progression.
No specific foods need to be avoided, but taking the capsule with a meal reduces gastrointestinal side effects. Limit excessive alcohol intake to protect liver health.
Some patients report mild eye irritation or photosensitivity; wearing sunglasses outdoors can help. If you notice significant visual disturbances, seek ophthalmologic evaluation.
Coverage varies by individual insurance plans and the Hospital Authority’s formulary. Patients should verify reimbursement eligibility with their insurer or hospital pharmacy.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be prepared to show it at customs if requested.
Ofev (nintedanib) targets multiple tyrosine kinases (PDGF, FGF, VEGF), whereas pirfenidone, another antifibrotic, primarily modulates transforming growth factor-β pathways. Both aim to slow lung function decline in IPF, but their side-effect profiles differ.
